CRADA

Bionic Power Launches $500,000 Agilik Movement Campaign on GoFundMe

Retrieved on: 
tisdag, maj 14, 2024
Insurance, Patient, Bangladesh Technical Education Board, CAD, Hemiparesis, Posture, Cerebral palsy, Friends, Life, Gait, GoFundMe, Movement, Hospital, Spina bifida, Fatigue, Child, KAFO, CRADA, Quality of life, Standard of care, Development, Walking, NIH, British Columbia Children's Hospital, Birth control

The Agilik Movement is a community-building campaign to crowdfund Agilik (TM) smart orthoses for children and teens with knee-extension deficiencies.

Key Points: 
  • To view an enhanced version of this graphic, please visit:
    For the Bionic Power team, the Agilik Movement is about raising awareness about the device and what it can do.
  • While the Agilik Movement campaign is focused specifically on young people, the Agilik device is also for adults.
  • The Agilik is the result of a Cooperative Research and Development Agreement (CRADA) between the National Institutes of Health Clinical Center and Bionic Power.
  • People can watch Paxton's story, donate to the Agilik Movement campaign on GoFundMe, and learn more - including about eligibility requirements - at https://bionic-power.com/agilik-movement/

GigaGen Doses First Patient in Phase 1 Trial of Anti-CTLA-4 Oncology Drug Candidate GIGA-564 in Advanced Solid Tumors

Retrieved on: 
måndag, maj 20, 2024
Partnership, Patient, Bangladesh Technical Education Board, Infection, Immunodeficiency, Toxicity, Clinical trial, TTY, Head, Safety, SAN, CRADA, Biotechnology, NCI, Development, National Cancer Institute, Pharmaceutical industry

SAN CARLOS, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for immune deficiencies, infectious diseases and checkpoint resistant cancers, and a subsidiary of Grifols, announced today that the first patient has been dosed in a Phase 1 clinical trial evaluating the safety and tolerability of its anti-CTLA-4 oncology drug, GIGA-564, for the treatment of metastatic or locally advanced solid tumors.

Key Points: 
  • “The initiation of this Phase 1 trial with GIGA-564 marks a significant milestone as it is GigaGen’s first oncology asset to enter the clinic,” said Carter Keller, senior vice president of Grifols and head of GigaGen.
  • “We look forward to potentially translating the superior anti-tumor performance and reduced immune-related toxicity observed with GIGA-564 in pre-clinical studies into the clinical setting.
  • For more information about the trial, refer to clinicaltrials.gov identifier: NCT06258304 .
  • For patients interested in enrolling in this clinical trial, please call NCI’s toll-free number: 1-800-4-Cancer (1-800-422-6237) (TTY: 1-800-332-8615); visit the website: https://trials.cancer.gov; and/or email: [email protected].

Qurient Therapeutics Enters CRADA with the National Cancer Institute to Collaborate on a Phase 1/2 Clinical Study of Q901 in Combination with TROP2-ADC

Retrieved on: 
tisdag, maj 21, 2024
Research, Other Health, General Health, Pharmaceutical, Oncology, Genetics, Public Relations, Investor Relations, Clinical Trials, Science, Biotechnology, Communications, Health, Other Science, SCLC, Patient, Bangladesh Technical Education Board, DNA, Trial of the century, Safety, CDK7, ADC, Carcinoma, Gene, KRX, CRADA, NCI, Development, NIH, Pharmaceutical industry

Q901 is a highly selective CDK7 inhibitor under Phase 1/2 clinical development in the United States and South Korea.

Key Points: 
  • Q901 is a highly selective CDK7 inhibitor under Phase 1/2 clinical development in the United States and South Korea.
  • Under this CRADA, NCI and Qurient will collaborate on an NCI-sponsored Phase 1/2 clinical study of Q901 in combination with the TROP2-ADC in SCLC and other relapsed solid tumors, starting from combination dose escalation and evaluating the safety, efficacy, and potential synergy of this novel combination.
  • "The collaboration between the NCI and Qurient is based on the science discovered through independent research conducted by each institution," said Kiyean Nam, Ph.D., CEO of Qurient.
  • "We hope the new combination therapy will help patients with small cell lung cancer, where current therapeutic options are limited."

Terran Orbital’s GEOStare SV2 Captures 3 Years of Success in High-Resolution Imaging

Retrieved on: 
onsdag, maj 15, 2024
Technology, Professional Services, Interior Design, Science, Construction & Property, Engineering, Satellite, Research, Other Defense, Aerospace, Telecommunications, Contracts, Manufacturing, Networks, Defense, Mobile, Wireless, Finance, RSO, Publication, CRADA, LLNL, Multimedia, Resident Space Object, Entrepreneurship, Communications satellite

GEOStare SV2 represents a groundbreaking collaboration between Terran Orbital and Lawrence Livermore National Laboratory (LLNL).

Key Points: 
  • GEOStare SV2 represents a groundbreaking collaboration between Terran Orbital and Lawrence Livermore National Laboratory (LLNL).
  • GEOStare SV2’s success underscores Terran Orbital’s commitment to developing cutting-edge small satellite technologies that fuel space exploration advancements.
  • To learn more about the mission, click here: Terran Orbital GEOStare SV2 Mission .
  • To learn more about Terran Orbital’s new SmallSat GEO™ space vehicle, click here: Terran Orbital SmallSat GEO™

Virpax Pharmaceuticals Reports 2024 First Quarter Results and Recent Developments

Retrieved on: 
måndag, maj 13, 2024
Veterinary, Surgery, Medical Devices, Infectious Diseases, Hospitals, Practice Management, Biotechnology, Health, Pharmaceutical, Bangladesh Technical Education Board, Pain management, Post-traumatic stress disorder, Therapy, IND, Pentagon, Bankruptcy, FINANCIAL, Epilepsy, CNS, Policy, Research, Liposome, Human, Chronic pain, Hematology, Bupivacaine, CRADA, United, United States bankruptcy court, Development, Central nervous system, MET, Pharmaceutical industry

Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced its financial results for the three months ended March 31, 2024, and other recent developments.

Key Points: 
  • Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced its financial results for the three months ended March 31, 2024, and other recent developments.
  • Nanomerics was recently awarded the United Kingdom’s most prestigious business award, the King’s Award for Enterprise 2024 in the innovation category.
  • On April 30, 2024, Virpax announced the results of Maximum Tolerated Dose Study for Probudur.
  • At March 31, 2024, Virpax had cash of approximately $1.9 million.

Maxwell Biosciences Enters Second CRADA with USAMRIID to Test Claromer Compounds as Potential Therapeutics for Viral and Bacterial Pathogens

Retrieved on: 
onsdag, maj 8, 2024
Infection, Collection, Research, Development, Therapy, CRADA, USAMRIID, Peptide, Biological warfare, Pharmaceutical industry

USAMRIID to study antiviral and antibacterial activity of Claromer technology against national priority biodefense threats.

Key Points: 
  • Part of the U.S. Army Medical Research and Development Command, USAMRIID is the U.S Army's premier institution and facility for defensive research into countermeasures against biological warfare, located on Fort Detrick, Maryland.
  • USAMRIID will test Maxwell Biosciences' Claromer peptoids for use as an antiviral therapeutic agent in USAMRIID's established in vivo infection models and as an antibacterial therapeutic against USAMRIID's bacterial select agent collection.
  • Pending successful results from initial testing and by mutual agreement, small animal dosing and tolerability tests would also be performed by USAMRIID.
  • "Entering a second collaborative research and development agreement with USAMRIID, the world's preeminent biodefense research organization, demonstrates the remarkable momentum behind Maxwell's Claromer platform technology," said J.Scotch McClure, CEO of Maxwell Biosciences.

QIAGEN partners with FBI to develop digital PCR assay for QIAcuity for use in forensics

Retrieved on: 
tisdag, maj 7, 2024
Assistant director, Accuracy and precision, HID, FBI, QIAGEN, Male, Research, FBI Laboratory, Workflow, NGS, Ageing, PCR, DNA, CRADA, QGEN, Soil, Nested polymerase chain reaction, Audit

The collaboration aims to develop a first-of-its-kind digital PCR (dPCR) assay that can simultaneously quantify in absolute terms nuclear and mitochondrial DNA concentrations, male DNA, and include quality markers for degradation and inhibition.

Key Points: 
  • The collaboration aims to develop a first-of-its-kind digital PCR (dPCR) assay that can simultaneously quantify in absolute terms nuclear and mitochondrial DNA concentrations, male DNA, and include quality markers for degradation and inhibition.
  • Forensic samples often contain very small amounts of DNA, which can be further compromised by age or environmental factors such as soil.
  • Compared to traditional quantitative PCR, dPCR offers a higher tolerance to inhibitors and enables forensic specialists to detect and quantify even minimal amounts of DNA with high accuracy.
  • This novel digital PCR assay could benefit the FBI and other forensic laboratories.

Verizon Frontline and NOAA to partner on advanced disaster response research

Retrieved on: 
måndag, maj 6, 2024
National Weather Service, Weather, NOAA, Social media, News, Travel, Verizon Communications, Cyclone, Partnership, Research, National Severe Storms Laboratory, Tornado, Water, Life, Uncrewed vehicle, Development, Environment, CRADA, Science, NWS, Private sector, Organization

BASKING RIDGE, N.J., May 06, 2024 (GLOBE NEWSWIRE) -- The National Oceanic and Atmospheric Administration (NOAA) and Verizon Frontline have signed a three-year Cooperative Research and Development Agreement to explore new strategies to rapidly deploy uncrewed aircraft systems to collect and distribute imagery of damage resulting from severe storms such as tornadoes or hurricanes.

Key Points: 
  • As part of this partnership, the Verizon Frontline Crisis Response Team will provide the uncrewed aircraft system platform, sensor, and personnel resources needed to rapidly respond and collect aerial imagery of storm-damaged areas of interest identified by NOAA.
  • The goal is to enhance the ability of NOAA’s National Weather Service offices to quickly conduct post-storm damage assessments, while also providing data for research conducted by the NOAA National Severe Storms Laboratory.
  • NOAA regularly partners with private sector companies through CRADAs to conduct research and development work that is mutually beneficial and helps to accomplish NOAA’s mission.
  • See how NOAA science, services and stewardship benefit your community: Visit noaa.gov for our latest news and features , and join us on social media .

ORYZON Reports Financial Results and Corporate Update for Quarter Ended March 31, 2024

Retrieved on: 
måndag, maj 6, 2024
Charcot–Marie–Tooth disease, FDA, Venetoclax, OHSU, Innovation, National Cancer Institute, BPD, Development, IND, CNS, NET, Schizophrenia, EVOLUTION, JHU, Azacitidine, NCI, FCCC, Deficit spending, IP, Paclitaxel, IIS, Food, European Patent Convention, CMT, Borderline personality disorder, Communication, Conference, AML, Aggression, Convertible bond, FMS, ALS, Phase, Kabuki syndrome, HOPE, Safety, SCLC, DSM-IV codes, EMA, Clinical trial, Medicine, EPO, Investigational New Drug, Duration, Platinum, Bangladesh Technical Education Board, Phase II, MRD, ICIS, MSKCC, Disease, Measure (mathematics), CRADA, Dor, Patent, HDAC6, Data analysis, Genomics, Pharmaceutical industry

Dr Carlos Buesa, Oryzon’s Chief Executive Officer, said: “Oryzon continued with a strong path in its clinical programs in the first quarter.

Key Points: 
  • Dr Carlos Buesa, Oryzon’s Chief Executive Officer, said: “Oryzon continued with a strong path in its clinical programs in the first quarter.
  • Research and development (R&D) expenses were $2.6 million for the quarter ended March 31, 2024, compared to $4.4 million for the quarter ended March 31, 2023.
  • General and administrative expenses were $0.9 million for the quarter ended March 31, 2024, compared to $1.2 million for the quarter ended March 31, 2023.
  • Net losses were $1.1 for the quarter ended March 31, 2024, respectively, compared to $1.4 million for the quarter ended March 31, 2023.

Toyota and Argonne National Laboratory Investigate Recycling of Lithium-Ion Batteries

Retrieved on: 
tisdag, april 30, 2024
Ecosystem, ANN, Argonne National Laboratory, Biophysical environment, Research, Manganese, Cobalt, Carbon, Development, Carbon footprint, CRADA, Toyota Motor North America, Recycling, Woven Planet Holdings, Nickel

ANN ARBOR, Mich., April 30, 2024 /PRNewswire/ -- Toyota Motor North America ('Toyota') announces that it has entered a Cooperative Research and Development Agreement (CRADA) with the U.S. Department of Energy's Argonne National Laboratory to investigate the development of a direct recycling process for lithium-ion batteries, which are prevalent in new electric vehicles. The focus of the research will be on cathode chemistries made of nickel, manganese, and cobalt.

Key Points: 
  • ANN ARBOR, Mich., April 30, 2024 /PRNewswire/ -- Toyota Motor North America ('Toyota') announces that it has entered a Cooperative Research and Development Agreement (CRADA) with the U.S. Department of Energy's Argonne National Laboratory to investigate the development of a direct recycling process for lithium-ion batteries, which are prevalent in new electric vehicles.
  • For the project, Toyota will provide Argonne with both end-of-life and new Toyota batteries.
  • Argonne will adapt and test its patent-pending direct recycling process with the batteries.
  • The collaborative project with Argonne is part of Toyota's pursuit of designing a closed-loop battery ecosystem aimed at maximizing sustainability.